TNN - jaargang 125, nummer 8, december 2024
drs. H.R. Moes , dr. C.A.J. Vroomen , dr. B. Jacobs
Met belangstelling lazen we het artikel van Wijburg et al. over de herziening van de landelijke richtlijn Multiple Sclerose.1 De richtlijncommissie verdient lof voor hun nauwgezette werk en heldere verslaglegging in TNN. De richtlijnmodule over doelmatig voorschrijven trok onze speciale aandacht, omdat toepassing van rituximab bij MS veel geld kan besparen.
(TIJDSCHR NEUROL NEUROCHIR 2024;125(8):345–7)
Lees verderTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.